/this-little-piggie----157402234-5c8badbac9e77c0001ac181f.jpg)
If you listen to the official press releases coming out of NHS England, the £330 million Federated Data Platform (FDP) built by Palantir is the single greatest thing to happen to British healthcare since the invention of penicillin. We are told it has magically unlocked over 110,000 extra operations, slashed waiting lists by hundreds of thousands, and cut delayed patient discharges by over 15%.
It sounds like a done deal. But it isn't.
When you look past the glossy national statistics, a much more complicated reality appears. The massive performance improvements credited to Palantir's Foundry software are not happening evenly across the country. Instead, the big wins are being driven by a tiny handful of early adopter hospitals. Meanwhile, dozens of other trusts are either stalling, quietly resisting, or discovering that the software doesn't quite live up to the marketing hype.
We are treating a localized success story as a nationwide revolution, and that mistake could cost taxpayers dearly before the 2027 contract break clause arrives.
The Myth of the Universal Fix
The core problem with the national narrative is something data analysts call selection bias. The dazzling statistics used to defend the Palantir contract come almost entirely from early pilot sites like the Chelsea and Westminster Hospital NHS Foundation Trust.
Chelsea and Westminster was hailed as a national exemplar. They reported saving 90 staff hours a week through streamlined waiting list management and optimized operating theatre scheduling. It looked brilliant on paper. But when independent researchers took a closer look, the cracks began to show.
An investigation published by The BMJ revealed that the data used to praise the pilot was deeply flawed. The baseline used to measure Palantir's "success" was taken from late 2021—a period when hospitals were completely crippled by the Omicron Covid-19 wave and elective surgeries had ground to a virtual halt.
Any hospital on earth would show a massive recovery in surgery numbers compared to the darkest months of the pandemic, whether they used advanced American software or a standard paper whiteboard. When researchers compared the Palantir adopters against non-adopting hospitals over the same timeline, they found no meaningful difference in recovery rates. The unique impact of the FDP basically vanished.
Why a Few Big Winners Distort the Picture
In any massive IT rollout, a few highly motivated organizations will always make the tech work. If a hospital trust has an army of in-house data engineers, a tech-savvy executive board, and millions in extra funding, they can bend almost any software to their will.
But the NHS has over 200 acute trusts, and the vast majority of them do not look like Chelsea and Westminster or University Hospitals Sussex. They are running on shoestring budgets, using ancient legacy computers, and dealing with staff who are too exhausted to learn a completely new data system.
What works beautifully in a well-funded London pilot trust falls flat when you drop it into a struggling regional hospital. Right now, about 69% of health service trusts have adopted the platform in some capacity, but "adopted" often just means they signed the paperwork. On the ground, clinicians are still staring at conflicting screens, updating physical whiteboards, and using pens.
By averaging the massive, resource-heavy wins of a few hospitals across the entire network, the government is hiding a uncomfortable truth: the platform is failing to deliver broad, systemic value to the frontline.
The Secret Rebellion in the Shires
While the government pushes for total compliance, a quiet rebellion is growing among local health boards. The Greater Manchester Integrated Care Board, which oversees healthcare for 2.8 million people, openly refused to sign up for the Palantir platform. Their reasoning was direct: they already had better, locally tailored data solutions in-house, and the outstanding security risks of the FDP hadn't been properly addressed.
This highlights a massive issue that the national strategy completely ignores: the risk of vendor lock-in.
When a hospital adopts the FDP, it isn't just buying middleware; it is moving its entire operational data infrastructure into an ecosystem controlled by a single US tech giant. Over time, local, trusted data tools get driven out. Once those local systems die, the trust loses its autonomy. If the NHS decides to walk away from Palantir in the future, transitioning decades of integrated hospital data to another provider will be an absolute logistical nightmare.
The Core Value Conflict
You can't talk about Palantir without talking about its baggage. The company was built with funding from the CIA's venture capital arm and spent its formative years creating software for the US military, the NSA, and immigration enforcement agencies like ICE.
The Commons Science, Innovation and Technology Committee released a damning report pointing out a "clear mismatch" between Palantir's corporate background and the fundamental values of the NHS. This isn't just political grandstanding from the left; it is a major operational risk.
Public healthcare relies entirely on patient trust. If patients believe their confidential medical records—ranging from mental health history to immigration status—are being funneled through a platform built by a defense contractor, they will stop sharing accurate information with their doctors. The UK's National Data Guardian, Nicola Byrne, recently demanded urgent clarity after discovering that some Palantir staff had been granted access to identifiable patient data, contradicting earlier promises from executives.
When doctors and patients don't trust the system, the system stops working. The British Medical Association even passed a motion opposing the rollout, creating a hostile environment where frontline consultants are actively resisting using the software.
How to Handle the 2027 Break Clause
The NHS has a multi-million-pound decision to make. The initial phase of the Palantir contract runs until February 2027, at which point the government has a legal break clause to terminate the deal.
We shouldn't wait until the final hour to scramble for a backup plan. Hospital executives and Integrated Care Boards need to take specific steps right now to protect their operations and taxpayer money.
First, stop expanding the FDP blindly based on national statistics. Local trusts must run independent, rigorous audits comparing their Palantir-driven metrics against historical baselines that don't rely on skewed pandemic data. If the software isn't delivering a clear, unique advantage over your old systems, pause the rollout.
Second, protect your local data talent. Do not dismantle your in-house analytics teams or scrap locally tailored software systems in favor of the centralized platform. You need to maintain a parallel data capability so you have an immediate safety net if the national contract gets torn up.
Finally, demand total transparency regarding data architecture. Trust boards must insist on clear, legally binding guarantees showing exactly which Palantir employees have access to patient records, what statutory basis allows it, and how they plan to decouple the data if the UK invokes the 2027 break clause.
The narrative that Palantir is a flawless savior for the NHS is officially dead. It's time to start looking at the real numbers, listening to the local trusts that are opting out, and planning for a healthcare data strategy that belongs to the public, not a foreign defense contractor.
